Ductal carcinoma in situ: Morphology-based knowledge and molecular advances

Advances in Anatomic Pathology

Volumn 20, Issue 4, 2013, Pages 205-216

  Ross, Dara S ^a   Wen, Yong Hannah ^a   Brogi, Edi ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast; Intrinsic subtypes; Invasive carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN B1; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE TRANSFERASE M1; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; SURVIVIN; UVOMORULIN;

CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CELL POLARITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; INTRADUCTAL CARCINOMA; LOBULAR CARCINOMA IN SITU; MITOSIS; NUCLEOLUS; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880181027     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182976ed5     Document Type: Review

References (71)

1. DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409-418.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
3. Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005;14:1008-1011. (Pubitemid 40478573)
4. Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102: 170-178.
5. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19: 924-930. (Pubitemid 32176266)
6. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102: 627-637.
7. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO Classification of Tumours of the Breast. Lyon, France: IARC Press; 2012.
8. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133: 1515-1538.
9. Brogi E, Murray MP, Corben AD. Lobular carcinoma, not only a classic. Breast J. 2010;16(suppl 1):S10-S14.
10. Rosen PP. Lobular carcinoma in situ and atypical lobular hyperplasia. In: Pine JW Jr, ed. Rosen's Breast Pathology. Philadelphia, PA: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2009:637-689.
11. Rakha EA, Gandhi N, Climent F, et al. Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. Am J Surg Pathol. 2011;35:1093-1103.
12. Wynveen CA, Nehhozina T, Akram M, et al. Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical followup. Am J Surg Pathol. 2011;35:1-14.
13. Tsang WY, Chan JK. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics. Am J Surg Pathol. 1996;20:921-943. (Pubitemid 26250633)
14. Farshid G, Moinfar F, Meredith DJ, et al. Spindle cell ductal carcinoma in situ. An unusual variant of ductal intra-epithelial neoplasia that simulates ductal hyperplasia or a myoepithelial proliferation. Virchows Arch. 2001;439:70-77. (Pubitemid 32662520)
15. Cheng L, Al-Kaisi NK, Gordon NH, et al. Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease. J Natl Cancer Inst. 1997;89:1356-1360. (Pubitemid 27418026)
16. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103:1137-1146. (Pubitemid 40328083)
17. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455-1461. (Pubitemid 29220544)
18. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24:1031-1036. (Pubitemid 46638798)
19. Rudloff U, Brogi E, Reiner AS, et al. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breastconserving therapy. Ann Surg. 2010;251:583-591.
20. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol. 2007;31:427-437. (Pubitemid 46673117)
21. Yeh IT, Mies C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med. 2008;132:349-358. (Pubitemid 351328810)
22. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19:617-621.
23. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271. (Pubitemid 43117611)
24. Otterbach F, Bankfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000;37: 232-240.
25. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol. 2001;195:415-421. (Pubitemid 33069665)
26. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10: 5367-5374. (Pubitemid 39100473)
27. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38:197-204. (Pubitemid 46096566)
28. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991;15:209-221.
29. Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011;24:917-923.
30. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992; 16:1133-1143. (Pubitemid 23004420)
31. MacGrogan G, Arnould L, de Mascarel I, et al. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions. Histopathology. 2008;52:689-697. (Pubitemid 351600053)
32. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer. 2011;2: 232-261.
33. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol. 2012;30:1268-1273.
34. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 1999;187:396-402. (Pubitemid 29118269)
35. Buerger H, Otterbach F, Simon R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189:521-526.
36. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31: 417-426. (Pubitemid 46673116)
37. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32:513-524.
38. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
39. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98: 10869-10874. (Pubitemid 32878711)
40. Cancer Genome, Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
41. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376. (Pubitemid 351413917)
42. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350-7360. (Pubitemid 46202348)
43. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-750.
44. Hannemann J, Velds A, Halfwerk JB, et al. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 2006;8:R61.
45. Muggerud AA, Hallett M, Johnsen H, et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol. 2010;4:357-368.
46. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14:370-378. (Pubitemid 351226103)
47. Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008;14:1956-1965. (Pubitemid 351551104)
48. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008;10:R67.
49. Zhou W, Jirstrom K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer. 2010;10:653.
50. van der Groep P, van Diest PJ, Menko FH, et al. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J Clin Pathol. 2009;62: 926-930.
51. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205:248-254.
52. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57:171-192.
53. Balleine RL, Webster LR, Davis S, et al. Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008;14:8244-8252.
54. Lee RJ, Vallow LA, McLaughlin SA, et al. Ductal carcinoma in situ of the breast. Int J Surg Oncol. 2012;2012:123549.
55. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1:362-375. (Pubitemid 36437922)
56. Abba MC, Drake JA, Hawkins KA, et al. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res. 2004;6: R499-R513.
57. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 2006;66:5278-5286. (Pubitemid 43844952)
58. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003;100:5974-5979. (Pubitemid 36576916)
59. Knudsen ES, Ertel A, Davicioni E, et al. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat. 2012;133:1009-1024.
60. Hernandez L, Wilkerson PM, Lambros MB, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol. 2012; 227:42-52.
61. Heselmeyer-Haddad K, Berroa Garcia LY, Bradley A, et al. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am J Pathol. 2012;181:1807-1822.
62. Lee S, Stewart S, Nagtegaal I, et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res. 2012;72:4574-4586.
63. Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet. 2005;37: 899-905. (Pubitemid 41077119)
64. Shin SJ, Simpson PT, Da Silva L, et al. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Am J Surg Pathol. 2009;33:496-504.
65. Geyer FC, Lacroix-Triki M, Colombo PE, et al. Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology. 2012;60(6B): E115-E130.
66. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010; 28:3762-3769.
67. Collins LC, Achacoso N, Sharafali Z, et al. Predictors of local recurrence in patients with ductal carcinoma in situ treated by breast conserving therapy: value of the Memorial- Sloan-Kettering nomogram [abstract]. Mod Pathol. 2012; 25:118.
68. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95:1692-1702. (Pubitemid 37509078)
69. Solin LJ, Baehner FL, Butler S, et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision without irradiation for ductal carcinoma in situ: a prospective validation study of the DCIS score from ECOG E5194 [abstract]. San Antonio Breast Cancer Symposium: S4-6. Cancer Res. 2011;71(suppl 3).
70. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319-5324.
71. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma of the breast. J Natl Cancer Inst. 2013;105:701-710.